Prospective studies conducted in Western populations have suggested that alterations in soluble CD27 (sCD27) and soluble CD30 (sCD30), two markers indicative of B-cell activation, are associated with risk of non-Hodgkin lymphoma (NHL). Given that the characteristics of NHL in East Asia differ from the West and mechanistic commonalities between these populations with respect to the role of intermediate endpoint biomarkers in lymphomagenesis have not been explored, we conducted a pooled nested case-control study from three prospective studies of Chinese men and women including 218 NHL cases and 218 individually matched controls. Compared with the lowest quartile, ORs (95% CIs) for the second, third and fourth quartiles of sCD27 were 1.60 (0.83–3.09), 1.94 (0.98–3.83) and 4.45 (2.25–8.81), respectively (ptrend = 0.000005). The corresponding ORs for sCD30 were 1.74 (0.85–3.58), 1.86 (0.94–3.67) and 5.15 (2.62–10.12;ptrend = 0.0000002). These associations remained statistically significant in individuals diagnosed with NHL 10 or more years after blood draw. Notably, the magnitude of the associations with NHL risk was very similar to those in Western populations in previous studies. These findings of the similar association between sCD27 or sCD30 and NHL risk across different populations support an important underlying mechanism of B-cell activation in lymphomagenesis.What's new?
Risk of non-Hodgkin lymphoma (NHL) may be foreshadowed by elevated levels of soluble CD27 and CD30, markers reflective of chronic B-cell activation. These associations are based on evidence from Western populations, but the present study shows that alterations in soluble CD27 and CD30 are also linked to future NHL risk in Chinese men and women. As with individuals of European descent, in Asians the associations persisted for 10 or more years before NHL diagnosis. The data suggest that a common mechanism involving B-cell activation may underlie NHL development across populations, despite differences in NHL incidence and subtype distribution.